Healthcare entity
CyPath Lung is the most frequent co-covered peer, appearing in 2 of the 2 tracked stories. The 60-day window averages about 0.2 stories each week. Each story carries 2 original sources on average, compared with 3.3 for the broader beat in this window.
Last mentioned: 6d ago
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
CyPath Lung is the most frequent co-covered peer, appearing in 2 of the 2 tracked stories. The 60-day window averages about 0.2 stories each week. Each story carries 2 original sources on average, compared with 3.3 for the broader beat in this window. At 5.5, the average consequence score sits below the same-window beat average of 5.9. Coverage clusters in health-it, which accounts for 1 of those 2, with the remainder spread across 1 other category. bioAffinity Technologies, Inc. appears in 2 tracked Healthcare stories published from July 8, 2026 through September 5, 2026.
Computed from the 2 stories linked to this entity, with beat comparisons drawn from all 470 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering bioAffinity Technologies, Inc.. Shared-story counts are live from our verified record — not editorial picks.
bioAffinity's CyPath Lung test volume grew 216% year over year, and the company is now expanding into post-treatment surveillance for lung-cancer patients. The move could widen the test's clinical role beyond initial diagnostic decisions.
bioAffinity Technologies reported a record Q2 for its CyPath® Lung noninvasive test, with sales more than doubling year-over-year and physician adoption accelerating. The test, designed to help evaluate indeterminate lung nodules, has now been used nearly 3,000 times across pulmonology and VA settings. The trend underscores the demand for noninvasive early cancer diagnostics in an expanding screening population.
Source: Financialcontent · Businesswire
bioAffinity Technologies, Inc. is linked from 2 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
